{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:46:09Z","timestamp":1790286369119,"version":"4.1.0"},"reference-count":41,"publisher":"SAGE Publications","issue":"11","license":[{"start":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T00:00:00Z","timestamp":1758067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Psychopharmacol"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Clozapine has anti-suicidal properties and significant effects on sleep. Sleep disturbances are associated with suicide risk. Daytime somnolence and sedation are commonly reported adverse effects of clozapine treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims:<\/jats:title>\n                    <jats:p>Systematic review and meta-analysis of somnolence in randomized controlled trials (RCTs) of patients with schizophrenia treated with clozapine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We systematically searched PubMed, PsycINFO, and Web of Science databases. We included RCTs, in English, with data on somnolence in patients with schizophrenia treated with clozapine versus other antipsychotics. Data were pooled using a random effects model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Twenty-two RCTs (2991 patients: 1404 on clozapine and 1587 on other antipsychotics) met inclusion criteria. Patients treated with clozapine had a significantly increased odds of somnolence compared to other antipsychotics (36.3% vs 21.9%, OR\u2009=\u20092.06, 95% CI: 1.65\u20132.57,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u20090.01). Clozapine was also associated with significantly increased odds of somnolence compared to olanzapine and risperidone. In meta-regression analyses, clozapine dose, age, sex, race, and publication year were unrelated to the association.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Clozapine is associated with significantly more somnolence, compared to other antipsychotics. A greater mechanistic understanding of associations between sleep changes and suicide risk in patients treated with clozapine is needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/02698811251364385","type":"journal-article","created":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T05:46:01Z","timestamp":1758174361000},"page":"1277-1283","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Meta-analysis of clozapine and somnolence in schizophrenia"],"prefix":"10.1177","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-8436-0843","authenticated-orcid":false,"given":"Matthew R","family":"Hopkins","sequence":"first","affiliation":[{"name":"Medical College of Georgia, Augusta University, Augusta, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5056-4515","authenticated-orcid":false,"given":"Brian J","family":"Miller","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Health Behavior, Augusta University, Augusta, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,9,17]]},"reference":[{"key":"e_1_3_2_2_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.158.8.1305"},{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2003.09.033"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.155.4.499"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.151.1.20"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.155.6.751"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-198712000-00002"},{"key":"e_1_3_2_8_1","first-page":"269","article-title":"Clozapine efficacy in schizophrenic nonresponders","volume":"24","author":"Conley RR","year":"1988","unstructured":"Conley RR, Schulz SC, Baker RW, et al. (1988) Clozapine efficacy in schizophrenic nonresponders. Psychopharmacol Bull 24: 269\u2013274.","journal-title":"Psychopharmacol Bull"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(86)90046-2"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1037\/1082-989X.6.2.161"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/bmb\/ldaa024"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.33734"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-199705000-00001"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v60n0109"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0243437"},{"key":"e_1_3_2_16_1","first-page":"62","article-title":"Clozapine in treatment-resistant schizophrenics","volume":"24","author":"Kane JM","year":"1988","unstructured":"Kane JM, Honigfeld G, Singer J, et al. (1988) Clozapine in treatment-resistant schizophrenics. Psychopharmacol Bull 24: 62\u201367.","journal-title":"Psychopharmacol Bull"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.2165\/11586450-000000000-00000"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1177\/070674370304800208"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2011.12.017"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.4103\/IJPSYM.IJPSYM_111_17"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1996.01830120020005"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2007.04.043"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2023.02.106"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2022.12.011"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.2006.163.4.600"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.60.1.82"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/YCO.0000000000000856"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.5664\/jcsm.9646"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2023.01.018"},{"key":"e_1_3_2_30_1","first-page":"307","article-title":"Results of a comparative double blind study with clozapine and chlorpromazine in the treatment of schizophrenic patients","author":"Niskanen P","year":"1974","unstructured":"Niskanen P, Achte K, Jaskari M (1974) Results of a comparative double blind study with clozapine and chlorpromazine in the treatment of schizophrenic patients. Psychiatr Fennica 307\u2013313.","journal-title":"Psychiatr Fennica"},{"key":"e_1_3_2_31_1","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. (2021) The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ 372: n71.","journal-title":"BMJ"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1177\/104012371502700404"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17101700"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2009.05.002"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2014.05.060"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.63.7.721"},{"key":"e_1_3_2_37_1","unstructured":"StataCorp (2007) Stata Statistical Software: Release 10. College Station TX: StataCorp LP."},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(01)00377-8"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2008.10.011"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(00)01026-X"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41537-025-00570-9"},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/sltb.13099"}],"container-title":["Journal of Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811251364385","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/02698811251364385","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811251364385","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:12:22Z","timestamp":1777507942000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/02698811251364385"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,17]]},"references-count":41,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1177\/02698811251364385"],"URL":"https:\/\/doi.org\/10.1177\/02698811251364385","relation":{},"ISSN":["0269-8811","1461-7285"],"issn-type":[{"value":"0269-8811","type":"print"},{"value":"1461-7285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,17]]}}}